DrugId:  1
1. Name:  Ketoconazole
2. Groups:  Approved, Investigational
3. Description:  Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. It is a racemate consisting of equimolar amounts of (2R,4S)- and (2S,4R)-ketoconazole with the chiral centers on the acetal ring.
4. Indication:  For the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.
DrugId:  2
1. Name:  Oteseconazole
2. Groups:  Investigational
3. Description:  Oteseconazole has been used in trials studying the treatment of Tinea Pedis, Onychomycosis, Candidiasis, Vulvovaginal, and Recurrent Vulvovaginal Candidiasis.
4. Indication:  Not Available
DrugId:  3
1. Name:  Candicidin
2. Groups:  Withdrawn
3. Description:  Candicidin is an antibiotic obtained from a streptomyces (Streptomyces griseus) and active against some fungi of the genus Candida (C. albicans). Candicidin is administered intravaginally in the treatment of vulvovaginal candidiasis.
4. Indication:  Used in the topical treatment of vulvovaginal candidiasis.
DrugId:  4
1. Name:  MK-3118
2. Groups:  Investigational
3. Description:  SCY-078 has been used in trials studying the treatment of Mycoses, Candidemia, Candidiasis, Invasive, and Vulvovaginal Candidiasis.
4. Indication:  Not Available
DrugId:  5
1. Name:  PAC-113
2. Groups:  Investigational
3. Description:  PAC-113 an anti-fungal, for the treatment of oral candidiasis infections. It is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva. In vitro studies demonstrate that it has potent anti-fungal activity against the Candida albicans, including drug-resistant HIV patient isolates. PAC-113 is targeting oral Candida infections in immunocompromised patients and patients with salivary dysfunction.
4. Indication:  Investigated for use/treatment in candidiasis, fungal infections, and saliva and salivary gland dysfunction.
DrugId:  6
1. Name:  Ravuconazole
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in fungal infections, aspergillosis, candidiasis, and onychomycosis.
DrugId:  7
1. Name:  Lexaptepid Pegol
2. Groups:  Investigational
3. Description:  Lexaptepid Pegol has been used in trials studying the treatment of Anemia, Inflammation, Chronic Diseases, End Stage Renal Disease, and Anemia of Chronic Disease.
4. Indication:  Not Available
DrugId:  8
1. Name:  Palifermin
2. Groups:  Approved
3. Description:  Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli.
4. Indication:  For treatment of oral mucositis associated with chemotherapy and radiation therapy.
DrugId:  9
1. Name:  ADC4022
2. Groups:  Investigational
3. Description:  ADC4022 is an investigational medicine for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and severe asthma.
4. Indication:  Investigated for use/treatment in asthma and chronic obstructive pulmonary disease (COPD).
DrugId:  10
1. Name:  ALKS 27
2. Groups:  Investigational
3. Description:  ALKS 27 is an inhaled formulation of trospium chloride for the treatment of chronic obstructive pulmonary disease (COPD). Study showed that ALKS 27 was well-tolerated over a wide dose range, with no dose-limited effects observed.
4. Indication:  Investigated for use/treatment in chronic obstructive pulmonary disease (COPD).
DrugId:  11
1. Name:  Inosine pranobex
2. Groups:  Approved
3. Description:  Inosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.
4. Indication:  Inosine pranobex is also indicated for mucocutaneous infections due to herpes simplex virus (type 1 and type II) and for treatment of genital warts as adjunctive therapy to podophyllin or carbon dioxide laser. 
DrugId:  12
1. Name:  Fluconazole
2. Groups:  Approved, Investigational
3. Description:  Triazole antifungal agent that is used to treat oropharyngeal candidiasis and cryptococcal meningitis in AIDS. [PubChem]
4. Indication:  For the treatment of fungal infections.
DrugId:  13
1. Name:  Boric acid
2. Groups:  Approved
3. Description:  Boric acid, also known as hydrogen borate, is a weak monobasic Lewis acid of boron with the chemical formula H3BO3. It is found as a component in cosmetics and pharmaceutical products in addition to industrial processes [4]. Boric acid can also be found in antiseptic products, as it exhibits antibacterial activity against infections such as bacterial vaginosis and candidiasis [1].
4. Indication:  No FDA- or EMA-approved therapeutic indications on its own.
DrugId:  14
1. Name:  Micafungin
2. Groups:  Approved, Investigational
3. Description:  Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
4. Indication:  For use in the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.
DrugId:  15
1. Name:  Foscarnet
2. Groups:  Approved
3. Description:  An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV. [PubChem]
4. Indication:  For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
DrugId:  16
1. Name:  Butoconazole
2. Groups:  Approved
3. Description:  Butoconazole is an imidazole antifungal used in gynecology.
4. Indication:  For the local treatment of vulvovaginal candidiasis (infections caused by Candida)
DrugId:  17
1. Name:  Voriconazole
2. Groups:  Approved, Investigational
3. Description:  Voriconazole (VfendÂ®, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections.
4. Indication:  For the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.
DrugId:  18
1. Name:  Famciclovir
2. Groups:  Approved, Investigational
3. Description:  Famciclovir is a guanine analogue antiviral drug used for the treatment of various herpes virus infections, most commonly for herpes zoster (shingles). It is a prodrug form of penciclovir with improved oral bioavailability. Famciclovir is marketed under the trade name Famvir (Novartis).
4. Indication:  For the treatment of acute herpes zoster (shingles). Also for the treatment or suppression of recurrent genital herpes in immunocompetent patients and treatment of recurrent mucocutaneous herpes simplex infections in HIV infected patients.
DrugId:  19
1. Name:  Milatuzumab
2. Groups:  Investigational
3. Description:  Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
4. Indication:  Not Available
DrugId:  20
1. Name:  Anidulafungin
2. Groups:  Approved, Investigational
3. Description:  Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin. [Wikipedia]
4. Indication:  For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis), Aspergillus infections, and esophageal candidiasis. Also considered an alternative treatment for oropharyngeal canaidiasis.
DrugId:  21
1. Name:  Posaconazole
2. Groups:  Approved, Investigational, Vet approved
3. Description:  Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
4. Indication:  For prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), or due to hematologic malignancies with prolonged neutropenia from chemotherapy. Also for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole. Posaconazole is used as an alternative treatment for invasive aspergillosis, Fusarium infections, and zygomycosis in patients who are intolerant of, or whose disease is refractory to, other antifungals.
DrugId:  22
1. Name:  BTA798
2. Groups:  Investigational
3. Description:  BTA798 is an antiviral for the treatment of HRV, the common cold virus, known to cause significant clinical complications in sufferers of Asthma and Chronic Obstructive Pulmonary Disease.
4. Indication:  Investigated for use/treatment in viral infection.
DrugId:  23
1. Name:  Tocofersolan
2. Groups:  Approved
3. Description:  Tocofersolan is a polyethylene glycol derivative of Î±-tocopherol and synthetic water-soluble version of vitamin E. Tocofersolan is an oral treatment of vitamin E deficiency due to digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis. It was approved by the European Medicines Agency (EMA) in June 2009 under the market name Vedrop. Tocofersolan is also used in cosmetics and pharmaceuticals as an antioxidant.
4. Indication:  Vedrop is indicated in vitamin E deficiency due to digestive malabsorption in paediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis, from birth (full term newborns) up to 18years of age. [EMA]
DrugId:  24
1. Name:  MLN-977
2. Groups:  Investigational
3. Description:  MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase. It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease. 
4. Indication:  Investigated for use/treatment in asthma and chronic obstructive pulmonary disease (COPD).
DrugId:  25
1. Name:  Isotretinoin
2. Groups:  Approved
3. Description:  Isotretinoin is a medication used for the treatment of severe acne. It is sometimes used in prevention of certain skin cancers. It is a retinoid, meaning it derives from vitamin A and is found in small quantities naturally in the body. Isotretinoin binds to and activates nuclear retinoic acid receptors (RAR), thereby regulating cell proliferation and differentiation. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.
4. Indication:  For the treatment of severe recalcitrant nodular acne
